American Society of Hematology, Blood, 25(130), p. 2718-2727
DOI: 10.1182/blood-2017-05-781849
Full text: Unavailable
Key Points Active infection pretransplant adversely impacts survival (81% in patients with active infection vs 95% in infection-free patients; P = .009). Preparative chemotherapy improved 1-year post-HCT median CD4 counts (P = .02) and freedom from IV immunoglobulin (P < .001).